277 filings
6-K
MESO
Mesoblast Ltd
17 Dec 20
Mesoblast Update on COVID-19 Ards Trial
9:54pm
6-K
MESO
Mesoblast Ltd
15 Dec 20
Mesoblast Provides Topline Results from Phase 3 Trial of Rexlemestrocel-l for Advanced Chronic Heart Failure
6:03am
6-K
MESO
Mesoblast Ltd
7 Dec 20
Fda Grants Fast Track Designation for Remestemcel-l In the Treatment of Acute Respiratory Distress Syndrome Due to COVID-19
6:04am
6-K
MESO
Mesoblast Ltd
1 Dec 20
Current report (foreign)
6:04am
6-K
MESO
Mesoblast Ltd
23 Nov 20
Current report (foreign)
6:05am
6-K
u2wapvcz74r
23 Nov 20
Mesoblast Enters Global Collaboration for Development, Manufacture and Commercialization of Remestemcel-l
6:04am
6-K
bzqvdcaem9xjvg304u
13 Nov 20
Second Interim Analysis of Clinical Outcomes after 135 Patients Results In Recommendation to Continue Remestemcel-l Phase 3 Trial In COVID-19 Ards
6:01am
6-K
8xmgre6v
3 Nov 20
Update on Remestemcel-l for the Treatment of COVID-19 Ards and Steroid-refractory Acute GVHD
12:00am
6-K
vkwz92
29 Oct 20
Current report (foreign)
6:02am
6-K
kuwz5h2lnk4vcd0e3
22 Oct 20
Current report (foreign)
9:45pm
6-K
1zbq65h ywsthw
15 Oct 20
Randomized Controlled Phase 3 Trial of Remestemcel-l for Reduced Mortality In COVID-19 Acute Respiratory Distress Syndrome Surpasses 50% Enrollment
12:00am
6-K
ucgz6f t9lsuxdh7oxi
2 Oct 20
Current report (foreign)
9:30pm
6-K
6oxllgd8z9vnrz7
17 Sep 20
Mesoblast Wins 2020 Fierce Biotech Innovation of the Year Award for Remestemcel-l
12:00am
6-K
m6giwdoig7d2avpdvz
16 Sep 20
Please fill in and submit as a PDF announcement+Rule 2.7
12:00am
6-K
qi1ik3culs330yugu
8 Sep 20
Current report (foreign)
7:31am
6-K
p7gvfd6yfk9
2 Sep 20
Mesoblast Receives Ethics Approval to Treat COVID-19 Patients In Australia
9:24pm
6-K
ldi7in9er27
28 Aug 20
Mesoblast Well Prepared Ahead of First Potential US Product Launch
8:48pm
6-K
3vs6at
25 Aug 20
Please fill in and submit as a PDF announcement+Rule 2.7
12:00am
6-K
tl9rxz zt
17 Aug 20
Current report (foreign)
12:00am